Institute of Cancer Research study of Zytiga contradicts NICE's rejection for advanced prostate cancer

5 February 2015

A study by the Institute of Cancer Research in London and the Royal Marsden NHS Foundation Trust has shown abiraterone significantly extends the lives of patients with advanced prostate cancer, if given before chemotherapy.

A major Phase III clinical trial of abiraterone, marketed as Zytiga by US health care giant Johnson & Johnson (NYSE: JNJ), showed that patients with advanced, aggressive prostate cancer lived more than four months longer on average if they received the drug before chemotherapy than if they did not.

Published in Lancet Oncology, the Phase III trial could fill a gap in previous evidence for the drug’s effectiveness pre-chemotherapy. A previous analysis published in 2013 showed that abiraterone before chemotherapy increased the time before cancer progressed but did not prove it gave an overall extension of life. The National Institute for Health and Care Excellence cited this when rejecting abiraterone pre-chemotherapy in guidance last year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK